Background: Patient characteristics and blood pressure-related outcomes in randomized clinical trials (RCTs) differ from clinical practice because of stringent selection criteria. The present study aimed to explore the relationship between clinical trials and clinical practice. We analyzed data from patients enrolled in the "Treatment with Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy" (EARLY) registry comparing blood pressure (BP) effects of the angiotensin receptor blocker (ARB) azilsartan medoxomil (AZL-M) with the angiotensin-converting enzyme (ACE) inhibitor ramipril between patients who met the eligibility criteria of a previous RCT and those who did not. Methods: Patients with primary arterial hypertension were consecutively enrolled from primary care offices in Germany into the EARLY registry in a 7:3 ratio for treatment with AZL-M or an ACE inhibitor, provided that they met the following criteria at baseline: 1) no antihypertensive treatment prior to inclusion or a non-renin-angiotensin system (RAS) based monotherapy; 2) initiation of treatment with either AZL-M or an ACE inhibitor alone. Analyses were performed to evaluate BP effects for patients in the EARLY registry who met the selection criteria of a prior RCT (RCT+) versus those who did not (RCT-). Results: Out of 3,698 patients considered, 1,644 complied with the RCT criteria (RCT+) while 2,054 did not (RCT-). RCT- patients (55.5 %) displayed a higher risk profile in terms of age and comorbidities, and a wider spectrum of BP values at baseline, as highlighted by the grades of hypertension and mean BP values. The proportion of patients who achieved target blood pressure control in the RCT+ group was significantly higher for AZL-M versus ramipril (64.1 versus 56.1 %; P < 0.01), in accordance with the result of the clinical trial. In the RCT- AZL-M group, the proportion of patients who met BP targets was lower (58.1 %) than in the RCT+ AZL-M group (64.1 %), whereas the proportion of patients with target BP values in the RCT- ramipril and the RCT+ ramipril groups was similar (57.7 versus 56.1 %). Thus, in contrast to results for the RCT+ group, in the RCT- group, the target BP attainment rate for AZL-M was not significantly superior to that for ramipril. However, the tolerability profile of AZL-M and ramipril was comparable in both populations. At the 12-month follow-up, death and stroke rates were low (≤0.5 %) and adverse events did not differ between the AZL-M and ramipril groups, irrespective of RCT eligibility. Conclusions: These data confirm that the EARLY population comprised a broader spectrum of hypertensive patients than RCTs, and the differences in patient characteristics were accompanied by disparate rates of blood pressure goal attainment. Overall, the validity of the RCT was demonstrated and confirmed in clinical practice with a broader range of patients with various comorbidities.
from #Medicine via ola Kala on Inoreader http://ift.tt/1S1iSdB
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
►
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
-
▼
2015
(2119)
-
▼
Δεκεμβρίου
(940)
-
▼
Δεκ 19
(31)
- The renin-angiotensin receptor blocker azilsartan ...
- Retrospective analysis of the efficacy of chemothe...
- Coverage of exposed hardware after lower leg fract...
- Clinical application of anterolateral thigh perfor...
- Role of circulating nesfatin-1 in the underweight ...
- Right arm injection of contrast medium reduces ven...
- Sensors, Vol. 15, Pages 32079-32122: Cloud-Based A...
- Sensors, Vol. 15, Pages 32056-32078: Robust Road C...
- Sensors, Vol. 15, Pages 32045-32055: Surface Acous...
- Molecules, Vol. 20, Pages 22833-22847: Properties ...
- Electrophysiological correlates of top-down effect...
- IJMS, Vol. 16, Pages 30382-30404: Effects of Heat ...
- Four trace elements in pregnant women and their re...
- Important role of shivering suppression during the...
- Quantitative assessment of cardiac electrical hete...
- Is diffusion-weighted imaging useful for different...
- Helicobacter pylori and cardiovascular disease: an...
- Efficacy of paclitaxel in the treatment of Kaposi ...
- Ratios, Ratios and Ratios of white blood count for...
- Sensors, Vol. 15, Pages 32031-32044: A Simulation ...
- Sensors, Vol. 15, Pages 32020-32030: Technological...
- Arts, Vol. 4, Pages 121-122: Sounding Science: Exp...
- Materials, Vol. 8, Pages 8868-8876: Surface Effect...
- Religions, Vol. 6, Pages 1433-1456: Sensing Religi...
- Sensors, Vol. 15, Pages 31999-32019: One Small Ste...
- Remote Sensing, Vol. 7, Pages 17297-17311: Toward ...
- IJMS, Vol. 16, Pages 30382-30404: Effects of Heat ...
- IJMS, Vol. 16, Pages 30362-30381: Tissue Regenerat...
- Sustainability, Vol. 7, Pages 16783-16800: Natural...
- IJMS, Vol. 16, Pages 30362-30381: Tissue Regenerat...
- Molecules, Vol. 20, Pages 22799-22832: Pharmacopho...
-
▼
Δεκ 19
(31)
-
▼
Δεκεμβρίου
(940)
Αναζήτηση αυτού του ιστολογίου
Σάββατο 19 Δεκεμβρίου 2015
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
https://ift.tt/2MQ8Ai8
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.